Skip to main content
Canna~Fangled Abstracts

Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach.

By October 23, 2013No Comments
[Epub ahead of print]

pm2Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach.

Source

Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada; Alcohol Research and Treatment Clinic, Addiction Medicine Services, Ambulatory Care and Structured Treatments, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada; Department of Psychiatry and Institute of Medical Sciences, University of Toronto, Toronto, Canada. Electronic address: bernard.lefoll@camh.ca.

Abstract

Tobacco produces an impressive burden of disease resulting in premature death in half of users. Despite effective smoking cessation medications (nicotine replacement therapies, bupropion and varenicline), there is a very high rate of relapse following quit attempts. The use of efficient strategies for the development of novel treatments is a necessity. A ‘bench to bedside strategy’ was initially used to develop cannabinoid CB1 receptor antagonists for the treatment of nicotine addiction. Unfortunately, after being tested on experimental animals, what seemed to be an interesting approach for the treatment of nicotine addiction resulted in serious unwanted side effects when tested in humans. Current research is focusing again on pre-clinical models in an effort to eliminate unwanted side effects while preserving the initially observed efficacy. A ‘bed side to bench strategy’ was used to study the role of the insula (part of the frontal cortex) in nicotine addiction. This line of research started based on clinical observations that patients suffering stroke-induced lesions to the insula showed a greater likelihood to report immediate smoking cessation without craving or relapse. Subsequently, animal models of addiction are used to explore the role of insula in addiction. Due to the inherent limitations existing in clinical versus preclinical studies, the possibility of close interaction between both models seems to be critical for the successful development of novel therapeutic strategies for nicotine dependence.
© 2013.

KEYWORDS:

ALPHA-4 beta-2 nicotinic receptor, AM251, AM4113, BOLD, CB(1), CB(1) putative neutral antagonist, CB(2), CPP, Cyclic Adenosine Monophosphate, D1 receptor antagonist, DBS, Dependence, EU, European Union, FDA, Food and Drug Administration, GABA, GABAb, Hypocretin-1, K(i), Nicotine, Reinstatement, Rimonabant, SCH23390, TAS-20, Therapy, Toronto Alexithymia Scale, Treatment, VTA, WHO, World Health Organization, Zinc Finger Transcription Factor, blood–oxygen-level dependent, cAMP, cannabinoidreceptor type 1, cannabinoid receptor type 2, conditioned place preference, deep brain stimulation, fMRI, functional magnetic resonance imaging, gamma-aminobutyric acid, inhibition constant, inverse agonist at the CB(1) cannabinoid receptor, kDa, kiloDalton, metabotropic transmembrane receptor for gamma-aminobutyric acid Gamma-aminobutyric acid, nAChRs, nM, nanomolar, nicotinic receptor subunit, nicotinic receptors, orexin-A, rTMS, transcranial magnetic stimulation, ventral tegmental area, zif-268, α4β2, β2

PMID:

 

24140878

 

[PubMed – as supplied by publisher] potp font 1